PLSCR1通过降低细胞表面ACE2的调节来抑制SARS-CoV-2感染
Ruiyi Ma1,2, Xinyi Zhang3, Ruonan Li1,2
1NHC Key Laboratory of System Biology of Pathogens, and Christophe Merieux Laboratory National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
脂杂交酶1 (PLSCR1) 通过减少细胞表面上的ACE2来限制SARS-CoV-2. 这一发现为开发针对COVID-19的抗病毒疗法提供了新的途径,通过准宿主-病原体相互作用.
科学领域:
- 这是天生的免疫力.
- 病毒学 病毒学
- 分子生物学分子生物学
背景情况:
- I型干扰素诱导干扰素刺激基因 (ISG) 来对抗SARS-CoV-2.
- 大多数针对SARS-CoV-2的ISG的精确抗病毒机制仍然不完全理解.
- 识别新型宿主限制因素对于理解病毒病原和开发治疗方法至关重要.
研究的目的:
- 为了确定新的干扰素刺激基因 (ISG),限制SARS-CoV-2 (COVID-19) 感染.
- 阐明脂 scramblase 1 (PLSCR1) 抑制 SARS-CoV-2 进入的机制.
- 探索针对PLSCR1介导的限制的治疗潜力.
主要方法:
- 对109个ISG淘汰细胞系进行查,以确定抗病毒因素.
- 使用伪型和真实的SARS-CoV-2来评估病毒进入.
- 在血和整体细胞水平上量化ACE2表达.
主要成果:
- 脂 scramblase 1 (PLSCR1) 被确定为对SARS-CoV-2的关键限制因素.
- 缺乏PLSCR1的细胞表现出对SARS-CoV-2感染的敏感性增加.
- 通过降低血膜ACE2表达的调节,PLSCR1的过度表达抑制了SARS-CoV-2感染.
结论:
- PLSCR1充当关键宿主限制因子,抑制SARS-CoV-2的进入.
- 该机制涉及血ACE2,病毒受体的特定下调.
- 这些发现提供了对宿主对SARS-CoV-2的天生的免疫力的见解,并建议潜在的抗病毒治疗策略.
更多相关视频
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
10:16SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
Published on: January 6, 2017
相关概念视频
Experimental RNAi
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
GPCR Desensitization
GPCRs Regulate Adenylyl Cylase Activity
Leaky Scanning
